Announcements Trials
Browse Landscape

Phase

Phase 1 13Phase 1/2 9Phase 2 8Phase NA 3Phase EARLY_PHASE1 2Phase 4 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 48Gastrointestinal 10Genitourinary 6Head & Neck 5Gynecologic 4Breast 4Sarcoma 3Dermatologic 3CNS 3Other hematologic neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Thyroid Carcinoma, Anaplastic 3Thyroid Cancer, Papillary 3Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Thyroid Neoplasms 2Somatostatinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Laryngeal Neoplasms 2Hematologic Neoplasms 2Glioma 2Gastroenteropancreatic Neuroendocrine Tumors 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2Vipoma 1Thyroid cancer, Hurthle cell 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Muscle Weakness 1Motor Activity 1Melanoma 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡